TIDMALM
RNS Number : 7791Q
Allied Minds PLC
22 June 2015
Media Contact:
Christine Dunn
ArcPoint Strategic Communications
cdunn@arcpointstrategy.com
617.484.1660 x101
Allied-Bristol Life Sciences Licenses Intellectual Property from
Harvard University
-- Allied-Bristol Life Sciences (ABLS) has licensed intellectual
property developed in Professor Malcolm Whitman's laboratory at
Harvard.
-- The intellectual property includes lead molecules and a
differentiated mechanism to develop drugs for treating chronic
fibrotic and autoimmune diseases.
Boston (June 22, 2015) - Allied-Bristol Life Sciences, LLC, a
biopharmaceutical enterprise jointly owned by Allied Minds (LSE:
ALM) and Bristol-Myers Squibb Company (NYSE: BMY), today announced
that it has entered into a licensing agreement with Harvard
University based on research and intellectual property developed in
Professor Whitman's lab at the Harvard School of Dental
Medicine.
Malcolm Whitman, PhD, Professor of Developmental Biology, and
Tracy Keller, PhD, an instructor in the Department of Developmental
Biology, have identified the mechanism of action behind a known
natural product, halofuginone (HF). HF is a chemical compound based
on an active ingredient in the root of the blue evergreen hydrangea
(Dichroa febrifuga), which has been used in traditional Chinese
medicine for centuries.
Building on previous studies conducted with Mark Sundrud, PhD,
and Anjana Rao, PhD, at Boston Children's Hospital, Professor
Whitman's lab, in collaboration with Professor Ralph Mazitschek,
PhD, at the Center for Systems Biology at Massachusetts General
Hospital, has shown that HF works through inhibition of Prolyl-tRNA
synthetase, which leads to activation of an amino acid restriction
(AAR) response pathway. Based on this novel and differentiated
mechanism, several lead molecules have been identified by the
groups at HMS and MGH that have the potential to lead to effective
therapy for several conditions including fibrotic and autoimmune
diseases.
"Our research is at the right stage for an infusion of resources
and expertise to accelerate its progression," said Dr. Whitman. "We
look forward to seeing the development of lead compounds from our
laboratories into novel therapeutics for the treatment of fibrotic
disease, and potentially other indications."
"The work done by Whitman and Keller is a terrific example of a
promising early-stage therapeutic application that has the
potential to make a significant difference to patients," said
Satish Jindal, Chief Executive Officer of ABLS. "We are pleased to
support this project through the next phase of drug discovery to
identify a candidate for clinical development. This is a great
example of the type of university research that ABLS looks for,
where our expertise and experience can accelerate bringing new
therapies to patients that need them."
The licensing agreement with Harvard's Office of Technology
Development is among the first in a series of discovery and
development projects that Allied-Bristol Life Sciences intends to
pursue. The license to the technology from Professor Whitman's lab
will be held by a new ABLS subsidiary specifically formed to pursue
further research and pre-clinical development of the technology and
associated molecules.
For more information about Allied-Bristol Life Sciences, please
visit www.ablifescience.com.
About Allied-Bristol Life Sciences
Allied-Bristol Life Sciences (ABLS) is a jointly owned
enterprise between Allied Minds and Bristol-Myers Squibb Co. Based
upon compelling biological discoveries and insights from scientists
at leading U.S. research institutions, ABLS identifies, sources and
de-risks promising, early-stage therapeutic opportunities, from
discovery through pre-clinical development, in key therapeutic
areas, including fibrosis, cardiovascular diseases, oncology,
immunology, virology and genetically defined diseases. For more
information, visit www.ablifescience.com.
About Harvard University's Office of Technology Development
Harvard's Office of Technology Development (OTD) is responsible
for all activities pertaining to the evaluation, patenting and
licensing of new inventions and discoveries made at Harvard
University and Harvard Medical School. Harvard OTD also serves to
further the development of Harvard technologies through the
establishment of sponsored research collaborations with industry.
The mission of Harvard OTD is to promote the public good by
fostering innovation and translating new inventions made at Harvard
into useful products that are available and beneficial to society.
For more information, please visit http://otd.harvard.edu.
About Allied Minds
Allied Minds (LSE: ALM) is an innovative U.S. science and
technology development and commercialization company. Operating
since 2006, Allied Minds forms, funds, manages and builds products
and businesses based on innovative technologies developed at
leading U.S. universities and federal research institutions. Allied
Minds serves as a diversified holding company that supports its
businesses and product development with capital, central management
and shared services. More information about the Boston-based
company can be found at www.alliedminds.com.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit www.bms.com, or
follow us on Twitter at http://twitter.com/bmsnews.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the company's regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Listing Rules and the
Disclosure and Transparency Rules, neither the company nor any
other party intends to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee
that the licensing agreement mentioned in this release will lead to
identifying a pre-clinical candidate. Nor is there any guarantee
that if one is identified, it will be successfully developed for or
approved for any of the indications described in this release.
Forward-looking statements in this press release should be
evaluated together with the many uncertainties that affect
Bristol-Myers Squibb's business, particularly those identified in
the cautionary factors discussion in Bristol-Myers Squibb's Annual
Report on Form 10-K for the year ended December 31, 2014 in our
Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K.
Bristol-Myers Squibb undertakes no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events or otherwise.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUASRRVAANUUR
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2023 to Apr 2024